Global Cyclosporine Drug Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Indication;

Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye and Others.

By Route of Administration;

Oral and Parenteral.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn105377290 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Cyclosporine Drug Market (USD Million), 2021 - 2031

In the year 2024, the Global Cyclosporine Drug Market was valued at USD 1641.47 million. The size of this market is expected to increase to USD 2160.07 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.0%.

The healthcare system faced significant challenges during the COVID-19 pandemic, leading to the postponement or restriction of outpatient treatments to minimize viral transmission risks. This affected the management of chronic therapies, including the use of the anti-inflammatory drug cyclosporine, which was explored for its potential in managing COVID-19 infections. However, clinical trials for cyclosporine in COVID-19 were reported as futile, resulting in decreased usage for this purpose and potential long-term consequences.

Despite pandemic-related setbacks, the Global Cyclosporine Drug Market is driven by factors such as the increasing prevalence of target diseases like inflammatory and autoimmune conditions. For example, psoriasis affects a significant portion of the global population, with cyclosporine being a widely used treatment due to its ability to provide rapid symptom relief. Moreover, developments such as the approval of new formulations like Verkazia for vernal keratoconjunctivitis by the FDA in June 2021 contribute to market growth, alongside the need for efficient therapies and competition among market players.

Nevertheless, challenges such as a lack of disease awareness in developing regions may hinder market growth in the forecast period. Despite this, the market for cyclosporine drugs continues to hold significant growth potential driven by factors such as new product approvals, expanding therapeutic applications, and increasing demand for effective treatments worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Region
  4. Global Cyclosporine Drug Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Autoimmune Disease Prevalence
        2. Expanding Applications
        3. Cost-Effective Alternative
      2. Restraints
        1. Side Effects
        2. Strict Regulations
        3. Development of New Drugs
      3. Opportunities
        1. Generic Drugs
        2. Research & Development
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Cyclosporine Drug Market, By Indication, 2021 - 2031 (USD Million)
      1. Transplant Rejection Prophylaxis
      2. Rheumatoid Arthritis
      3. Psoriasis
      4. Autoimmune Myasthenia Gravis
      5. Dry Eye
      6. Others
    2. Global Cyclosporine Drug Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Parenteral
    3. Global Cyclosporine Drug Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis Inc
      2. ALLERGAN
      3. Teva Pharmaceuticals
      4. AbbVie Inc
      5. Sun Pharmaceuticals
  7. Analyst Views
  8. Future Outlook of the Market